A Mitochondria-Targeted Flavokawain A Derivative Suppresses Lymphoma by Disrupting Oxidative Phosphorylation

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Diffuse large B-cell lymphoma (DLBCL) presents significant therapeutic challenges due to drug resistance and relapse.
• Standard treatments for DLBCL often face limitations, necessitating novel therapeutic strategies.

Purpose of the Study:

• To develop and evaluate TPP-FLA, a mitochondria-targeted derivative of Flavokawain A (FLA), for its antilymphoma activity.
• To elucidate the underlying mechanisms of TPP-FLA's action against lymphoma cells.

Main Methods:

• TPP-FLA was synthesized by conjugating Flavokawain A (FLA) with triphenylphosphonium (TPP).
• Antiproliferative activity and apoptosis induction were assessed in lymphoma cell lines.
• Mitochondrial membrane potential, oxidative stress, and mitochondrial superoxide accumulation were measured using JC-1, TMRM, DCFH-DA, and MitoSOX Red staining.
• Transcriptomic and DIA-based proteomic analyses were performed to investigate metabolic pathway disruption.

Main Results:

• TPP-FLA demonstrated significantly enhanced antiproliferative activity and apoptosis induction compared to FLA.
• TPP-FLA induced mitochondrial dysfunction, including membrane potential collapse and increased oxidative stress.
• Mitochondria-derived superoxide accumulation was specifically promoted by TPP-FLA.
• Transcriptomic and proteomic analyses revealed disruption of mitochondrial energy metabolism, particularly oxidative phosphorylation.

Conclusions:

• Mitochondria-targeted TPP-FLA exhibits superior antilymphoma activity compared to FLA.
• TPP-FLA effectively induces lymphoma cell death by targeting mitochondrial function, oxidative stress, and energy metabolism.
• TPP-FLA represents a promising mitochondria-targeted therapeutic candidate for lymphoma treatment.